Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00857519 · ClinicalTrials.gov registry record · NA
A Study of the Effectiveness of a Local Injection of Chemotherapy for Retinoblastoma
A NA study, sponsored by Wills Eye.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT00857519 is a NA study that has completed, run by Wills Eye. The registered enrollment target is 10 participants.
The verdict
NCT00857519, a NA study, has completed, sponsored by Wills Eye.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
Over the past 15 years, intravenous chemotherapy has become the most popular conservative (eye-saving) method for retinoblastoma treatment because it is often effective and usually safe. In recent years, there has been much interest in providing highly focused (focal) chemotherapy to a diseased organ including the liver, brain, and eye. With focused chemotherapy, the chemotherapy drugs are injected directly into the ophthalmic artery (the artery that supplies blood to the eye). A benefit of focal chemotherapy delivery is that it decreases the chance of toxicity to other organs such as bone marrow suppression (causing low blood counts) and the development of other cancers in the future.
Interventions
- DRUG Melphalan, Carboplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2009-01 |
| Est. Completion | 2014-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00857519
The ClinicalTrials.gov registry entry for NCT00857519 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wills Eye, which has 59 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Melphalan, Carboplatin is the first listed.
NCT00857519 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00857519 about?
NCT00857519 is a clinical study titled "A Study of the Effectiveness of a Local Injection of Chemotherapy for Retinoblastoma". Over the past 15 years, intravenous chemotherapy has become the most popular conservative (eye-saving) method for retinoblastoma treatment because it is often effective and usually safe. In recent years, there has been much interest in providing highly focused (focal) chemotherapy to a diseased orga...
What is the current status of trial NCT00857519?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2009-01. Estimated completion is 2014-04.
What interventions are being tested in trial NCT00857519?
The interventions under investigation include: Melphalan, Carboplatin (DRUG).
Who is sponsoring clinical trial NCT00857519?
This trial is sponsored by Wills Eye, which has 59 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.